Start Date
October 1, 2014
Primary Completion Date
May 1, 2017
Study Completion Date
May 1, 2017
BMN 673
Starting oral dose of 1.0 mg once daily to be taken until progression, death, unacceptable toxicity, withdrawal consent or any other criterion felt by the Investigator to preclude continuation of treatment.
Royal Sussex County Hospital, Brighton
The Beatson West of Scotland Cancer Centre, Glasgow
St Bartholomew's Hospital, London
University College Hospital, London
The Christie Hospital, Manchester
Western General Hospital, Edinburgh
The Churchill Hospital, Oxford
Velindre Cancer Centre, Cardiff
St James's University Hospital, Leeds
Royal Marsden Hospital (Sutton), Sutton
The Clatterbridge Cancer Centre, Bebington
Bristol Haematology and Oncology Centre, Bristol
East Kent Hospitals University NHS Foundation Trust, Kent
The Royal Marsden Hospital (London and Surrey), London and Surrey
Guy's Hospital, London
Northern Centre for Cancer Care, Newcastle
Collaborators (1)
Medivation, Inc.
INDUSTRY
University College, London
OTHER